The hunt is on for a cure and vaccines for COVID-19. Piper Sandler says Remdesivir could be approved very soon for COVID-19.
Earlier in the month, Pfizer Inc was reported to be considering a collaboration with German drugmaker BioNTech SE to develop vaccines for COVID-19 using BioNTech's mRNA-based drug development platform, Pfizer's R&D head told Reuters on Thursday.
Reuters reported that Pfizer Chief Scientific Officer Mikael Dolsten was one of the pharmaceutical executives who attended a meeting with US President Donald Trump to discuss possible vaccines and treatments for the fast-spreading virus at the start of this month.
"Dolsten also gave more details about the company's efforts to develop potential anti-viral treatments for the virus, which are currently being screened by a third-party company to see how it performs against the virus in a laboratory setting.
Pfizer said these compounds could potentially be used in conjunction with another antiviral treatment being developed by Gilead Sciences GILD.O called remdesivir, which is further along in the development process."
Key notes
- Pfizer's compounds use a different mechanism of action than Gilead's to attack the virus, Dolsten said, with Pfizer's looking to attack the protease segment of the virus.
- The protease "is one of the best drug targets in the viral sector," Dolsten said. "It has been one of the most effective for HIV and HCV and our analysis confirmed that the COVID-19 protease target was very similar to one we had been working on for another virus."
- Gilead CEO Daniel O'Day said that remdesivir is in late stage clinical trials in both China and the United States. He said the company should know "in the next couple of months" whether the drug helps treat patients with the coronavirus.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD accelerates losses to 1.0930 on stronger Dollar
The US Dollar's recovery regains extra impulse sending the US Dollar Index to fresh highs and relegating EUR/USD to navigate the area of daily troughs around 1.0930 in the latter part of Friday's session.
GBP/USD plummets to four-week lows near 1.2850
The US Dollar's rebound keep gathering steam and now sends GBP/USD to the area of multi-week lows in the 1.2850 region amid the broad-based pullback in the risk-associated universe.
Gold trades on the back foot, flirts with $3,000
Gold prices are accelerating their daily decline, steadily approaching the critical $3,000 per troy ounce mark as the Greenback's rebound gains extra momentum and US yields tighten their retracement.
Can Maker break $1,450 hurdle as whales launch buying spree?
Maker holds steadily above $1,250 support as a whale scoops $1.21 million worth of MKR. Addresses with a 100k to 1 million MKR balance now account for 24.27% of Maker’s total supply. Maker battles a bear flag pattern as bulls gather for an epic weekend move.
Strategic implications of “Liberation Day”
Liberation Day in the United States came with extremely protectionist and inward-looking tariff policy aimed at just about all U.S. trading partners. In this report, we outline some of the more strategic implications of Liberation Day and developments we will be paying close attention to going forward.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.